Noninvasix Inc. received a breakthrough device designation from the FDA for its noninvasive Livox central venous oxygenation monitor, which allows real-time monitoring of central venous oxygen ...
重症敗血症患者を対象としたALBIOS試験の後ろ向き解析を実施。試験登録時の中心静脈血酸素飽和度（ScvO2）70％未満の514例と70％以上の961例でScvO2 70％未満の持続と死亡率の関連を評価した。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results